Comparative Pharmacology
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULLA.
SULFONAMIDES DUPLEX vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic